Literature DB >> 27141387

Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer.

Stalin Chellappa1, Harald Hugenschmidt2, Morten Hagness3, Pål D Line4, Knut J Labori5, Gro Wiedswang6, Kjetil Taskén7, Einar M Aandahl3.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is highly infiltrated by CD4+T cells that express RORγt and IL-17 (TH17). Compelling evidence from the tumor microenvironment suggest that regulatory T cells (Treg) contribute to TH17 mediated inflammation. Concurrently, PDAC patients have elevated levels of pro-inflammatory cytokines that may lead to TH17 associated functional plasticity in Treg. In this study, we investigated the phenotype and functional properties of Treg in patients with PDAC. We report that PDAC patients have elevated frequency of FOXP3+Treg, which exclusively occurred within the FOXP3+RORγt+Treg compartment. The FOXP3+RORγt+Treg retained FOXP3+Treg markers and represented an activated subset. The expression of RORγt in Treg may indicate a phenotypic switch toward TH17 cells. However, the FOXP3+RORγt+Treg produced both TH17 and TH2 associated pro-inflammatory cytokines, which corresponded with elevated TH17 and TH2 immune responses in PDAC patients. Both the FOXP3+Treg and FOXP3+RORγt+Treg from PDAC patients strongly suppressed T cell immune responses, but they had impaired anti-inflammatory properties. We conclude that FOXP3+RORγt+Treg have a dual phenotype with combined pro-inflammatory and immunosuppressive activity, which may be involved in the pathogenesis of PDAC.

Entities:  

Keywords:  FOXP3; RORγt; Th17 cell; Th2 cell; plasticity; regulatory T Cells; suppression; surface Markers

Year:  2015        PMID: 27141387      PMCID: PMC4839385          DOI: 10.1080/2162402X.2015.1102828

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  54 in total

Review 1.  Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Int Immunopharmacol       Date:  2011-05-31       Impact factor: 4.932

2.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

3.  Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells.

Authors:  Allison L Bayer; Aixin Yu; Thomas R Malek
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

4.  Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

Authors:  Nobuyoshi Hiraoka; Kaoru Onozato; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 5.  The plasticity of human Treg and Th17 cells and its role in autoimmunity.

Authors:  Markus Kleinewietfeld; David A Hafler
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

6.  Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer.

Authors:  Nichole R Blatner; Mary F Mulcahy; Kristen L Dennis; Denise Scholtens; David J Bentrem; Joseph D Phillips; Soo Ham; Barry P Sandall; Mohammad W Khan; David M Mahvi; Amy L Halverson; Steven J Stryker; Anne-Marie Boller; Ashima Singal; Rebekka K Sneed; Bara Sarraj; Mohammed Javeed Ansari; Martin Oft; Yoichiro Iwakura; Liang Zhou; Andreas Bonertz; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie
Journal:  Sci Transl Med       Date:  2012-12-12       Impact factor: 17.956

7.  A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma.

Authors:  Yui-Hsi Wang; Kui Shin Voo; Bo Liu; Chun-Yu Chen; Burcin Uygungil; William Spoede; Jonathan A Bernstein; David P Huston; Yong-Jun Liu
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

8.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

9.  Spectrum of cancer risk among US solid organ transplant recipients.

Authors:  Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin
Journal:  JAMA       Date:  2011-11-02       Impact factor: 157.335

10.  TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

Authors:  Liang Zhou; Jared E Lopes; Mark M W Chong; Ivaylo I Ivanov; Roy Min; Gabriel D Victora; Yuelei Shen; Jianguang Du; Yuri P Rubtsov; Alexander Y Rudensky; Steven F Ziegler; Dan R Littman
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

View more
  24 in total

1.  Thymus-derived Foxp3+ regulatory T cells upregulate RORγt expression under inflammatory conditions.

Authors:  Juhao Yang; Mangge Zou; Joern Pezoldt; Xuyu Zhou; Jochen Huehn
Journal:  J Mol Med (Berl)       Date:  2018-10-24       Impact factor: 4.599

Review 2.  Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?

Authors:  I H Sahin; G Askan; Z I Hu; E M O'Reilly
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

Review 3.  Regulatory T Cell Plasticity and Stability and Autoimmune Diseases.

Authors:  Runze Qiu; Liyu Zhou; Yuanjing Ma; Lingling Zhou; Tao Liang; Le Shi; Jun Long; Dongping Yuan
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

Review 4.  Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.

Authors:  Ahmed Elaileh; Ashish Saharia; Lucy Potter; Flavio Baio; Afnan Ghafel; Maen Abdelrahim; Kirk Heyne
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 5.  The role of immune dysfunction in obesity-associated cancer risk, progression, and metastasis.

Authors:  Aneesha Kulkarni; Laura W Bowers
Journal:  Cell Mol Life Sci       Date:  2021-01-19       Impact factor: 9.261

Review 6.  Pancreatic cancer: branched-chain amino acids as putative key metabolic regulators?

Authors:  Lenka Rossmeislová; Jan Gojda; Katarína Smolková
Journal:  Cancer Metastasis Rev       Date:  2021-12-28       Impact factor: 9.264

7.  Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment.

Authors:  Masakazu Hashimoto; John David Konda; Stephanie Perrino; Maria Celia Fernandez; Andrew M Lowy; Pnina Brodt
Journal:  Mol Cancer Ther       Date:  2021-09-22       Impact factor: 6.009

8.  FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer.

Authors:  David Taggart; Andrew H Sims; Catherine Davidson; David W Lonergan; Marta Canel; Alan Serrels
Journal:  Br J Cancer       Date:  2022-09-22       Impact factor: 9.075

Review 9.  Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy.

Authors:  Ezekiel Maloney; Tanya Khokhlova; Venu G Pillarisetty; George R Schade; Elizabeth A Repasky; Yak-Nam Wang; Lorenzo Giuliani; Matteo Primavera; Joo Ha Hwang
Journal:  Int Rev Immunol       Date:  2017-09-29       Impact factor: 5.311

10.  Intratumoral Foxp3+RORγt+ T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients.

Authors:  Yuchao Fei; Yifan Cao; Yun Gu; Hanji Fang; Yifan Chen; Jieti Wang; Xin Liu; Kunpeng Lv; Xudong He; Chao Lin; Hao Liu; He Li; Hongyong He; Ruochen Li; Heng Zhang; Weijuan Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-05-12       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.